Haemonetics Corporation

Haemonetics Corporation has been granted 61 US utility patents between 2015 and 2025, placing Haemonetics Corporation at rank #5,593 across all assignees tracked by PlainPatent. This portfolio spans 22 distinct Cooperative Patent Classification (CPC) subclasses, averaging 23.8 claims per patent with primary concentration in A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR). As a US Corporation, Haemonetics Corporation is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 52.1/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 39 grants, compared with 22 in the 2015–2019 window — a +77% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Haemonetics Corporation's 23.8 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while a multi-domain presence across 22 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Haemonetics Corporation against peers pursuing similar technology classes.